Logos Global Management LP Decreases Stock Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Logos Global Management LP decreased its holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 84.7% in the second quarter, Holdings Channel reports. The fund owned 265,000 shares of the company’s stock after selling 1,465,000 shares during the quarter. Logos Global Management LP’s holdings in Dyne Therapeutics were worth $9,352,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Nisa Investment Advisors LLC lifted its holdings in shares of Dyne Therapeutics by 904.1% in the 2nd quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock valued at $26,000 after acquiring an additional 669 shares during the last quarter. Amalgamated Bank increased its position in shares of Dyne Therapeutics by 39.9% during the second quarter. Amalgamated Bank now owns 2,792 shares of the company’s stock worth $99,000 after acquiring an additional 796 shares during the period. Ameritas Investment Partners Inc. increased its position in shares of Dyne Therapeutics by 28.0% during the first quarter. Ameritas Investment Partners Inc. now owns 5,896 shares of the company’s stock worth $167,000 after acquiring an additional 1,291 shares during the period. Public Employees Retirement Association of Colorado purchased a new position in shares of Dyne Therapeutics during the second quarter worth approximately $203,000. Finally, Farallon Capital Management LLC purchased a new position in Dyne Therapeutics during the second quarter valued at approximately $212,000. Institutional investors own 96.68% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. Piper Sandler reissued an “overweight” rating and set a $53.00 price objective on shares of Dyne Therapeutics in a report on Monday. Oppenheimer reissued an “outperform” rating and set a $55.00 price objective on shares of Dyne Therapeutics in a report on Tuesday, September 3rd. JPMorgan Chase & Co. lifted their price objective on shares of Dyne Therapeutics from $39.00 to $43.00 and gave the company an “overweight” rating in a report on Tuesday, July 9th. StockNews.com lowered shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 16th. Finally, Stifel Nicolaus lifted their price objective on shares of Dyne Therapeutics from $41.00 to $66.00 and gave the company a “buy” rating in a report on Friday, August 16th. One research analyst has rated the stock with a sell rating, nine have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Dyne Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $51.40.

Dyne Therapeutics Stock Down 5.4 %

Shares of DYN opened at $34.63 on Tuesday. Dyne Therapeutics, Inc. has a twelve month low of $6.40 and a twelve month high of $47.45. The company has a 50 day moving average of $40.89 and a two-hundred day moving average of $33.71. The company has a market cap of $3.03 billion, a price-to-earnings ratio of -8.72 and a beta of 1.07.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.70) EPS for the quarter, topping the consensus estimate of ($0.72) by $0.02. On average, sell-side analysts expect that Dyne Therapeutics, Inc. will post -2.96 EPS for the current year.

Insider Transactions at Dyne Therapeutics

In other Dyne Therapeutics news, CEO John Cox bought 32,000 shares of Dyne Therapeutics stock in a transaction that occurred on Wednesday, September 4th. The stock was purchased at an average price of $33.04 per share, with a total value of $1,057,280.00. Following the completion of the acquisition, the chief executive officer now directly owns 8,000 shares in the company, valued at approximately $264,320. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, COO Susanna Gatti High sold 8,976 shares of the business’s stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $34.41, for a total transaction of $308,864.16. Following the completion of the sale, the chief operating officer now owns 131,636 shares of the company’s stock, valued at $4,529,594.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO John Cox bought 32,000 shares of the business’s stock in a transaction dated Wednesday, September 4th. The shares were bought at an average cost of $33.04 per share, with a total value of $1,057,280.00. Following the purchase, the chief executive officer now directly owns 8,000 shares of the company’s stock, valued at $264,320. The disclosure for this purchase can be found here. Over the last ninety days, insiders sold 12,705 shares of company stock worth $437,701. Company insiders own 20.77% of the company’s stock.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.